Last updated at 21 Jun 2024 05:10 AM
Director
DIN: 06413295
Sushant Yatish Attavar is currently associated with 3 companies in various capacities such as Director and Additional Director. They serve as a Director at VARDHAMAN REMEDIES PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 06413295.Sushant Yatish Attavar is currently involved in 2 different roles. Their most recent position is with MANTIS HEALTHCARE SOLUTIONS PRIVATE LIMITED as a Additional Director. The first company Sushant Yatish Attavar was appointed to as a director was VARDHAMAN REMEDIES PRIVATE LIMITED. Sushant Yatish Attavar is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
Sushant Yatish Attavar is currently associated with 3 companies in various capacities such as Director and Additional Director. They serve as a Director at VARDHAMAN REMEDIES PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 06413295.Sushant Yatish Attavar is currently involved in 2 different roles. Their most recent position is with MANTIS HEALTHCARE SOLUTIONS PRIVATE LIMITED as a Additional Director. The first company Sushant Yatish Attavar was appointed to as a director was VARDHAMAN REMEDIES PRIVATE LIMITED. Sushant Yatish Attavar is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
3
Male
India
Gain instant access to verified contact details.
Current Companies (3)
Current LLPs (0)
Past Companies (0)
2y 8m 1y 4m Interval
| Company Name | Designation | Date of Appointment |
|---|---|---|
| VARDHAMAN REMEDIES PRIVATE LIMITED | Director | 01-Oct-2012 |
| VARDHAMAN SKINCARE PRIVATE LIMITED | Director | 07-Feb-2014 |
| MANTIS HEALTHCARE SOLUTIONS PRIVATE LIMITED | Additional Director | 03-Feb-2020 |